7 lectures · 230 items
45 min
4 min
2 min
7 min
5 min
11 min
5 min
New AI decision-support tool for heart failure enters clinical validation: the STRATIFYHF study
Heart failure is common in people with atrial fibrillation detected during screening
Enhanced remote medication program boosts GDMT prescriptions for high CV or kidney risk in T2D patients
STRATIFY-HF A European collaboration to develop an AI based support system for risk stratification and early detection of heart failureEducation, exchange, guidance and interaction during EPCCS Summit 2019Complexities of managing heart failure
Slides | Complexities of managing heart failure
Praktičan vodič za dijagnostikovanje i lečenje srčane insuficijencije u primarnoj zdravstvenoj zaštiti (PZZ)Complexities of managing heart failure in primary care
Slides | Managing complex heart failure: a specialist view of the primary/ secondary interface
Slides | Managing heart failure in primary care: The GP perspective
Практична настанова по діагностиці та менеджменту серцевої недостатності в системі первинної медичної допомоги
Chronické srdcové zlyhávanie
EPCCS Practical Guidance on Heart Failure Diagnosis and Management in Primary CareEPCCS Heart Failure Guidance published as Clinical Intelligence in Br J Gen Prac
What’s the new evidence base for heart failure diagnosis & management?synergy between cardiac and extracardiac mechanisms and effects of novel therapies.
This narrative review frames heart failure with preserved ejection fraction (HFpEF) as a systemic disease driven by the convergence of obesity, type 2 diabetes, and chronic kidney disease, which…
A real-world cohort study of nearly 46,000 patients evaluated whether glucosuria on routine urinalysis serves as a practical proxy for adherence to SGLT2 inhibitors. After inverse probability…
This narrative review evaluates pharmacological strategies for preventing type 2 diabetes in individuals with obesity and insulin resistance. While metformin retains the strongest long-term evidence…
A Review.
A recent narrative review and phase 3 trial data (SURMOUNT-OSA) demonstrate that GLP-1 receptor agonists, including tirzepatide, reduce the apnea-hypopnea index by 20 to 24 events per hour in adults…
A Systematic Review and Meta-Analysis.
A systematic review and meta-analysis of 29 randomised controlled trials (n=67,873) evaluated the association between DPP-4 inhibitors and heart failure in adults with type 2 diabetes. Overall, DPP-4…
transcatheter tricuspid repair on top of medical therapy lowers death or heart failure hospitalisation at three years by 60 percent in severe tricuspid regurgitation
The hard-endpoint trial the tricuspid field lacked: 360 patients (mean 80 years, 56 percent women) with heart failure and severe tricuspid regurgitation in 29 German centres, randomised 2:1 to…
nurse-coordinated, digitally supported heart failure care lowers mortality by 22 percent and nearly doubles guideline therapy in India
Cluster-randomised trial in 22 Indian centres (57 percent rural): 1,507 adults with HFrEF, nurse-coordinated collaborative care with mobile health, structured counselling and real-time communication…
eplontersen misses its primary endpoint in ATTR cardiomyopathy, with only a nominal signal in patients not on a stabiliser
The largest ATTR-CM trial to date (1,432 patients, 130 centres) randomised eplontersen 45 mg every four weeks against placebo. The primary composite of cardiovascular death and recurrent…
an ICD for scar on CMR with LVEF 36 to 50 percent misses its primary endpoint but reduces sudden cardiac death, with benefit confined to patients under 70
353 patients with LVEF 36 to 50 percent on optimal therapy and myocardial scar on cardiovascular magnetic resonance (ischaemic or non-ischaemic, 18 centres in Australia, Germany and the UK) were…
aficamten improves symptoms and exercise capacity in non-obstructive HCM, the first positive trial ever in this population
Presented in Hot Line 1 at ESC Congress 2026 in Munich and published simultaneously in the NEJM: in 517 patients with symptomatic non-obstructive hypertrophic cardiomyopathy, aficamten improved both…
two phenotypes instead of three, an MRA for everyone, stages A to D and semaglutide for HFpEF with obesity
Presented in Munich on 28 August 2026 and published in the European Heart Journal: the first full revision of the ESC heart failure guideline since 2021. HFmrEF disappears (HFrEF now means LVEF below…
A Prespecified Secondary Analysis.
In a prespecified secondary analysis of the SELECT trial, researchers evaluated the effect of semaglutide on high-sensitivity C-reactive protein (hsCRP) in 17,604 patients with established…